Sunday · Nov 15, 2026 · Weekend Digest · regulation
FDA rejects Summit's lung cancer drug ivonescimab, citing no proven survival benefit
In a complete response letter, the FDA said the drug's progression-free survival benefit without a significant survival gain does not support a positive benefit-risk profile, according to Summit. The drug, developed with China's Akeso, would have been the first PD-1 x VEGF bispecific antibody approved in the US, BioSpace reported; it has been available in China since 2024.
Why it matters: The decision keeps the first drug of its class off the US market and shows the FDA requiring a survival benefit, not only slower disease progression, in this setting.
References
- Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License ApplicationSummit Therapeutics · smmttx.com · 2026-11-15
- FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsSTAT · statnews.com · 2026-11-15
- Summit's PD-1xVEGF rejected by FDA in lung cancerBioSpace · biospace.com · 2026-11-15